Akash Jain Ajcon Global
We believe Sun Pharmaceutical Industries is the best play in pharma space and investors can add this stock to their long-term portfolio. The company reported stellar Q1FY19 results and were above our expectations.
At CMP, of Rs 655 stock trades at a P/E of 43x at trailing 12 months which seems expensive in the near term after the recent rally.
However, considering the long term prospects of the company and expected approvals of its products pipeline after the USFDA's clearance of its Halol plant (after nearly 3 years of non-compliance), we believe investors will be rewarded in the longer term.
In addition, we believe improvement in Taro’s US business (declined in Q1FY19) in the coming quarters along with a ramp-up in India and non US markets such Europe (Q1FY19 growth of 22 percent in India coupled with 11 percent growth in ROW driven by key markets including Romania, Eastern Europe, and Asia) will help to sustain margins.
Disclaimer: The author is Vice President - Equity Research, Ajcon Global. The views and investment tips expressed by investment experts on Moneycontrol are their own, and not that of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
